Thiele, Maja http://orcid.org/0000-0003-1854-1924
Kamath, Patrick S. http://orcid.org/0000-0002-7888-1165
Graupera, Isabel
Castells, Antoni http://orcid.org/0000-0001-8431-2033
de Koning, Harry J. http://orcid.org/0000-0003-4682-3646
Serra-Burriel, Miquel
Lammert, Frank http://orcid.org/0000-0003-4450-7201
Ginès, Pere http://orcid.org/0000-0003-4657-4504
Article History
Accepted: 6 February 2024
First Online: 13 March 2024
Competing interests
: M.T. reports speakers fees from Madrigal, Takeda, Siemens Healthcare, Echosens, Norgine and Tillotts Pharma, and advisory fees from AstraZeneca, Boehringer Ingelheim, GE Healthcare and GSK. M.T. is co-founder and board member of Evido, and a board member of Alcohol & Society (a non-governmental organization). P.G. has received research funding from Gilead & Grifols. P.G. has consulted or attended advisory boards for Gilead, RallyBio, SeaBeLife, Merck, Sharp and Dohme (MSD), Ocelot Bio, Behring, Roche Diagnostics International and Boehringer Ingelheim, and received speaking fees from Pfizer. A.C. has received funding from Fundación Científica de la Asociación Española contra el Cáncer and Universal Diagnostics, consulting fees from Goodgut, Amadix and iVascular, and speaker fees from Medial EarlySign and Abbvie. P.S.K., I.G., H.J.d.K., M.S.-B. and F.L. declare no competing interests.